The PAXIS trial is a randomized study in VEXAS Syndrome, a hemato-inflammatory condition that can cause inflammation and lowered blood counts. The purpose of this website is to educate health care professionals about the ongoing research in this area and opportunities for patient enrollment.
To learn more about this trial, visit:
ClinicalTrials.gov EU CTISConsult your doctor or other qualified healthcare provider with any questions you may have regarding your medical condition, or treatments.
Enrollment will occur in the highlighted countries. For a full list of PAXIS clinical sites and site enrollment status, visit
ClinicalTrials.gov EU CTIS
Pacritinib (commercially known as VONJO®) was approved by U.S. Food and Drug Administration (FDA) on February 28, 2022 for the treatment of adults with myelofibrosis with a platelet count below 50 x 109/L, and has since been marketed in the US under the brand name VONJO®. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
